- Scancell Holdings confirms further encouraging results from its on-going Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody being developed for the treatment of patients with melanoma.

Updated data on patients with resected Stage III or Stage IV melanoma was presented in a poster at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Monday 1 June 2015.

The poster entitled: "A clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients: a vaccine to prevent recurrence" by PM Patel et al, demonstrates that the latest clinical data on patients with fully resected tumours is highly promising, and suggests that SCIB1 may uniquely offer protection from recurrence of melanoma with little associated toxicities.


· All 16 patients with resected disease (two in Part 1 and 14 in Part 2) are still alive.

· Survival times are very encouraging: median survival time for Stage III patients (n=9) and Stage IV patients (n=7) is 34 and 31 months, respectively.

· Only five patients (31%) have had a recurrence of the disease; all other patients have been disease-free for between 27 and 46 months since study entry* (median follow-up of 34 months).

· The median for disease-free survival and overall survival (when 50% of patients have progressed or died, respectively) have therefore not yet been reached.

· All 16 patients showed melanoma-specific immune responses.

· All patients who continued treatment showed strong T cell memory responses following three monthly boosts with SCIB1.

· SCIB1 was safe and well-tolerated, with no grade 4/5 toxicities observed other than those related to disease progression and one case of pneumonia.

At 10:06am: [LON:SCLP] Scancell Holdings PLC share price was -1.25p at 37p

Story provided by